D'AMICO, EMANUELE
 Distribuzione geografica
Continente #
EU - Europa 2.079
NA - Nord America 1.378
AS - Asia 309
OC - Oceania 7
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 2
Totale 3.783
Nazione #
US - Stati Uniti d'America 1.366
IE - Irlanda 1.240
SE - Svezia 388
IT - Italia 284
SG - Singapore 125
CN - Cina 107
FI - Finlandia 69
IR - Iran 39
ES - Italia 20
DE - Germania 19
GB - Regno Unito 18
TR - Turchia 12
CA - Canada 11
FR - Francia 8
IN - India 7
AU - Australia 6
HK - Hong Kong 6
BE - Belgio 5
NL - Olanda 5
RO - Romania 4
RU - Federazione Russa 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AT - Austria 3
CH - Svizzera 3
BR - Brasile 2
EG - Egitto 2
GR - Grecia 2
NP - Nepal 2
OM - Oman 2
PK - Pakistan 2
TH - Thailandia 2
UA - Ucraina 2
AM - Armenia 1
AR - Argentina 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
EC - Ecuador 1
IQ - Iraq 1
JP - Giappone 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.783
Città #
Dublin 1.238
Chandler 491
Nyköping 327
Princeton 134
Wilmington 83
Singapore 80
Helsinki 69
Ashburn 46
Des Moines 32
Rome 29
Shiraz 26
Ann Arbor 21
Serra de' Conti 20
Milan 16
Seattle 15
Los Angeles 14
Bari 12
Foggia 12
Granada 12
Guangzhou 12
Cedar Knolls 9
Kocaeli 8
Naples 8
Santa Clara 8
Jiaxing 7
Shanghai 7
London 6
New York 6
Palermo 6
St Louis 6
Tehran 6
Washington 6
Borås 5
Catania 5
Norwalk 5
Shenzhen 5
Villamagna 5
Beijing 4
Madrid 4
Melbourne 4
Pimonte 4
Pune 4
San Severo 4
Tsuen Wan 4
Wuhan 4
Boston 3
Camporotondo Etneo 3
Cesano Maderno 3
Florence 3
Genoa 3
Giulianova 3
Gravina di Catania 3
Hanover 3
Manfredonia 3
Nanjing 3
Nuremberg 3
Paris 3
Rui'an 3
Stockholm 3
Turin 3
Xuzhou 3
Almería 2
Andover 2
Ankara 2
Boardman 2
Brussels 2
Cagliari 2
Caltanissetta 2
Central 2
Chiang Mai 2
Clearwater 2
Concorezzo 2
Erzurum 2
Gavere 2
Kathmandu 2
Kitchener 2
Kollam 2
Maslianico 2
Muscat 2
Nottingham 2
Novokuznetsk 2
Orta Nova 2
Perugia 2
Pisa 2
Porto Garibaldi 2
Potenza 2
Quanzhou 2
Quweisna 2
Rincon de la Victoria 2
Romano di Lombardia 2
Santa Cristina Val Gardena 2
Santo Stefano Lodigiano 2
Spinazzola 2
Streatham 2
Tampa 2
Vienna 2
Waterford 2
Zibo 2
Ajax 1
Amsterdam 1
Totale 2.953
Nome #
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 117
Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019 79
MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case-control study 63
CCSVI and MS. A population-based case-control study in Catania, Sicily 61
Approccio clinico e possibilità di trattamento nella SLA 58
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 54
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 52
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 52
Effects of inpatient and outpatient rehabilitation setting on disability and quality of life of patients with multiple sclerosis: a randomized controlled study 50
Employment status in MS patients: a population-based study 50
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 49
Neuropsychological pattern of cognitive dysfunction in clinically isolated syndrome suggestive of MS 48
An update on the pharmacological management of pain in patients with multiple sclerosis 48
Comparison of Two Therapeutic Strategies in Active Relapsing-Remitting MS: Cyclophosphamide as Induction for 12 Months Follewed by Interferon Beta Versus Interferon Beta. A Two-Year Randomized Trial 48
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 47
Use of a low-cost, commercially available gaming console (Nintendo-WII) foe rehabilitation of patients with multiple sclerosis: results of a pilot study 46
Negative prognostic impact of spinal demyelinating lesions at clinical onset in relapsing-remitting multiple sclerosis 46
Dysphagia in Multiple Sclerosis 46
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal 46
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 45
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 45
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 44
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 44
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 43
IMMUNOSENESCENCE AND MULTIPLE SCLEROSIS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS 42
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 42
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 41
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 40
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 40
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 39
Association between dietary intake and function in amyotrophic lateral sclerosis 39
Unsatisfactory clinical and MRI response to DMTS in patients with late onset relapsing-remitting MS 39
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis 39
Management of dysphagia in multiple sclerosis: current best practice 39
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 39
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 39
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders 39
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 38
Can new chemical therapies improve the management of multiple sclerosis in children? 38
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 38
Multiple sclerosis patients preferences in decision making process 37
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 36
Gender related side effects of interferon-beta treatment in multiple sclerosis patients 36
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications 35
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 35
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 33
An update on the safety of treating relapsing-remitting multiple sclerosis 32
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 32
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 32
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019 31
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 31
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 31
Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register 30
Five insights from the Global Burden of Disease Study 2019 29
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019 29
Switching to immunosuppressant agents in secondary progresive multiple sclerosis patients: is it really effective? 28
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 27
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 27
Palliative care in progressive multiple sclerosis 27
The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 27
Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study 27
Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy 26
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 26
Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis 26
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 25
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 25
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 25
Autoimmune liver disease and multiple sclerosis: state of the art and future perspectives 25
Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults 24
Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies 24
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 24
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 24
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 24
Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis 24
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 24
Cognitive-motor dual-task interference:A systematic review of neural correlates 23
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 23
Serum and CSF N-acetyl aspartate Levels differ in multiple sclerosis and neuromyelitis optica 23
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 23
Treatment options of cognitive impairment in multiple sclerosis 23
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 23
Switching therapy: how and why in a real word setting cohort of persons with multiple sclerosis in Catania 23
Switching disease-modifying therapy in multiple sclerosis: escalation therapy has not an advantage on switching among same line drugs 23
Real-world comparison of safety profile in two groups of relapsing remitting multiple sclerosis on dimethyl-fumarate and teriflunomide therapy: preliminary results of a multicenter, prospective study 23
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 22
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 22
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 22
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 22
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 22
Prevalence of pain in multiple sclerosis: a multicenter italian study 22
Review: Patient-reported outcomes in multiple sclerosis care 22
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 21
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 21
Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives 21
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 21
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 21
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 21
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria 21
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 21
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 21
Totale 3.460
Categoria #
all - tutte 38.760
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.760


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202125 0 0 0 0 0 0 0 0 0 24 0 1
2021/2022893 5 0 1 0 363 30 14 47 97 93 21 222
2022/20232.656 270 115 199 121 48 210 16 182 1.373 45 52 25
2023/2024465 57 44 31 32 75 58 27 44 25 19 19 34
2024/2025254 110 71 68 5 0 0 0 0 0 0 0 0
Totale 4.293